Breaking AI & Tech News Analyzed

The Return of Tony SchumacherFour years after the critically acclaimed *The Responder*, Tony Schumacher returns with *The Cage*. While the premise suggests a standard casino heist thriller, the show quickly reveals itself to be a deeply moving state-of-the-nation piece that uses a gripping narrative to dissect the crushing weight of poverty, addiction, and familial duty.Beyond the Heist: A Deconstruction of Modern DespairThe story follows Leanne (Sheridan Smith) and Matty (Michael Socha), two casino employees who turn to robbery to escape their circumstances. However, Schumacher uses this narrative frame to explore the systemic failures trapping ordinary people.Leanne's Burden: A widowed mother caring for her grandmother with dementia, facing imminent eviction.Matty's Struggle: A recovering addict and gambling addict, estranged from his teenage daughter.Performance Analysis: Sheridan Smith and Michael SochaThe review highlights the chemistry and depth of the cast. Michael Socha is described as "phenomenal," excelling in a role that requires navigating humor, sorrow, and redemption. Sheridan Smith provides an infinitely credible performance as a woman standing on the edge of a precipice yet unable to step away due to her responsibilities.A State-of-the-Nation NarrativeUnlike *The Responder*, which focused on police, *The Cage* gives voice to the "whack-a-moles in trackie bottoms"—the victims of the system. It is a companion piece that empathizes more with the marginalized than with those attempting to corral them.Future OutlookThe show is currently available on BBC One and iPlayer, with strong indications of awards potential for the supporting cast, particularly Mona Goodwin, whose performance is noted for its depth despite limited screen time.

AI Takes Center Stage at Cannes' Parallel FestivalThe first edition of the World AI Film Festival (WAIFF) opened in Cannes this week, presenting a surreal lineup of AI‑crafted shorts ranging from fish‑scaled men to hyper‑realistic animal protagonists. While the official Cannes Film Festival barred AI entries from its Palme d’Or competition, the up‑start festival attracted big‑tech backers and Hollywood execs, branding the movement a new "nouvelle vague" of cinema. Numbers Behind the AI Film Surge5,000 AI‑created films submitted, up from 1,000 the previous year.Hollywood studios eye multiple $50m AI or hybrid productions instead of a single $200m conventional blockbuster.Swiss‑Italian filmmaker Dario Cirrincione produced a dementia‑themed short for €500 (≈£433), compared with an estimated €20,000 for traditional VFX. Legal and Ethical Friction Over CopyrightA short film echoing Aardman Animation's Wallace and Gromit was shortlisted, prompting director Mathieu Kassovitz to exclaim, "What the fuck?" The festival jury later withdrew the film, citing "strong resemblance to an existing work" and reaffirming its commitment to respecting copyright. The episode underscores ongoing tensions between AI model training on vast troves of human‑created content and the demand for creator compensation. Industry Ripple Effects of AI‑Generated CinemaExecutives like Joanna Popper (LA film and tech) and Marco Landi (former Apple Europe lead) highlighted AI's potential to lower production costs and accelerate shooting schedules. Yet veteran filmmakers such as Gong Li and Claude Lelouch expressed ambivalence, noting that AI excels at technical precision but often lacks narrative heart. The festival also featured a poignant €500 short on dementia, illustrating how AI can enable low‑budget storytelling that would otherwise be financially prohibitive. Future Trajectory of AI in FilmWith major studios pledging to integrate AI across the production pipeline, the next Cannes edition will again exclude AI works from competition, reaffirming the belief that "a film is not an assembly of data; it is a personal vision." However, as Marco Landi warned, the wave of AI adoption is rising: "Stay and the wave will destroy you, or learn to ride it." The coming months will likely see a hybrid model where AI tools augment human creativity while legal frameworks scramble to catch up.

The Breakthrough prize, often referred to as the 'Oscar of science', has been awarded to a team of scientists for their groundbreaking work in gene therapy. Jean Bennett, a molecular biologist, and Albert Maguire, an ophthalmologist, who met while dissecting a brain at Harvard Medical School, have been recognized for their 25-year-long project that led to the development of Luxturna, the first approved gene therapy for blindness.The therapy has transformed the lives of people born with Leber congenital amaurosis (LCA), a genetic disorder that typically causes total blindness by early adulthood. The treatment, which smuggles a working version of the gene into retinal cells, has shown profound improvements in patients, with one patient describing seeing their child's face for the first time.The $3m prize is shared with physician Katherine High, who worked with Bennett and Maguire on the project. The couple's work is a testament to their dedication and perseverance, with Bennett noting that she was 'overwhelmed' by the news and describing it as one of the most 'miraculous eureka moments' she could imagine.Bennett also expressed concerns about the US administration's attacks on science, warning that it could 'cause damage for generations to come' and lead to a brain drain that the country would struggle to recover from.The Breakthrough prizes, founded by Silicon Valley entrepreneurs, recognize outstanding achievements in life sciences, mathematics, and physics. Other prizes awarded included work on a gene therapy for sickle cell anaemia and beta thalassaemia, and the discovery of genetic drivers of frontotemporal dementia and ALS.

For the first time in Hollywood history, an authorized generative‑AI version of a major star headlines a feature film. The western As Deep As the Grave showcases a digitally recreated Val Kilmer, whose voice was synthesized by UK‑based firm Sonantic using archival recordings. The project, delayed by Kilmer’s death in April 2025, received full cooperation from his estate and his daughter Mercedes, who helped craft the visual deep‑fake of the actor. Mercedes Kilmer confirmed that her father embraced emerging technologies as a storytelling tool, a sentiment the filmmakers say they honored throughout production. At Wednesday’s CinemaCon trade show in Las Vegas, the trailer revealed that Kilmer’s character, Father Fintan—a Catholic priest and Native American spiritualist—appears for roughly one hour of screen time. The footage shows the priest at different ages, including a spectral elder who advises a child, “Don’t fear the dead and don’t fear me.” Writer‑director Coerte Voorhees explained that the narrative was built around Kilmer’s heritage and his love of the Southwest. He added that the production adhered to SAG‑AFTRA guidelines and that the estate was financially compensated for the use of archival material. The film also stars Tom Felton, Abigail Breslin and Abigail Lawrie. In a March interview with Variety, Voorhees noted that Kilmer’s family repeatedly emphasized the project’s importance to the late actor. The Kilmer case follows a growing trend of AI‑generated performances. In 2022, Bruce Willis consented to a digital twin after a dementia diagnosis, while actors such as Matthew McConaughey and Michael Caine have licensed their voices to AI firms for approved uses. Estates of legends like Laurence Olivier, Judy Garland and James Dean have similarly partnered with the marketplace ElevenLabs. Beyond film, celebrities are exploring AI for digital meet‑and‑greets; Paris Hilton and Kendall Jenner have reportedly signed deals with Meta for AI‑powered appearances on Instagram, and users can even query an AI version of Deepak Chopra for advice on a range of topics. Nevertheless, some stars remain cautious. Morgan Freeman, Tom Hanks and Scarlett Johansson have publicly expressed skepticism about deep‑fake replicas of their likenesses.

A recent Cochrane review analyzing 17 clinical trials involving over 20,000 people with mild cognitive impairment or dementia has concluded that anti-amyloid drugs have a 'trivial' effect on cognition and dementia severity over 18 months.The review, which assessed seven anti-amyloid drugs, found that improvements in functional ability were 'small at best' and that the drugs caused more swelling and bleeding in the brain than the placebo.The findings are a blow to the new wave of drugs designed to slow Alzheimer's by clearing clumps of amyloid protein that build up in the brain. Despite initial hype, with some regulators approving drugs like lcanemab and donanemab, many countries have stopped short of providing them through public health services due to concerns over their effectiveness and cost.Critics of the review argue that it combines results from older, failed drugs with those from newer, more effective medicines, which may skew the conclusions. However, the review's authors defend their approach, stating that all the drugs aimed to remove amyloid from the brain and assessed the impact on patients in a similar way.The review's lead author, Edo Richard, notes that the effect sizes are too small for patients and caregivers to notice, and that the drugs are also 'burdensome' due to the need for regular intravenous drug infusions and MRI scans.Experts in the field, such as Robert Howard, express concerns that the drugs may not truly alter the course of Alzheimer's, and that it's unfair to raise expectations in patients. Meanwhile, Alzheimer's Research UK argues that the review's conclusions are limited by its methodology and that anti-amyloid treatments will not be the whole answer to curing Alzheimer's.

The wait is over for fans of medical dramas, as The Pitt has landed on HBO Max. This 15-episode series, which follows the lives of medical staff in a Pittsburgh hospital, has been generating significant buzz since its release in the US last year.Produced by the same team behind the groundbreaking series ER, The Pitt stars Noah Wyle, known for his iconic role as Dr. John Carter in ER. Wyle plays Dr. Michael 'Robby' Robinavitch, a senior attending physician struggling with PTSD after the loss of his mentor during the pandemic.Each episode covers a single shift in the hospital, delving into the challenges faced by the medical staff as they navigate urgent and complex cases, from gunshot wounds to patients with dementia. The show's pace is more measured than ER, with a focus on character development and nuanced storytelling.The cast is strong, with well-developed characters and backstories that add depth to the narrative. Showrunner John Wells handles the large ensemble with skill, and Wyle is a rock-solid presence at the center of the show.The Pitt explores themes that are both timely and timeless, including the US healthcare system's flaws and the personal and professional struggles of medical staff. With its gripping storylines and strong performances, this series is sure to captivate audiences and leave them eager for more.

Legendary footballer John Toshack, known for his illustrious career with Liverpool FC and the Wales national team, has been diagnosed with dementia, according to his son Cameron. Toshack, 77, enjoyed a celebrated playing career with Liverpool from 1970 to 1978, scoring over 100 goals and securing nine major trophies, including three league titles, two UEFA Cups, an FA Cup, and a European Cup. He also earned 40 caps for Wales. After retiring as a player, Toshack transitioned into management, leading Swansea City from the fourth division to the top tier and later managing prestigious clubs such as Real Sociedad, Real Madrid, and his national team, Wales. Notably, he won La Liga with Real Madrid in 1990, scoring a record 107 goals that season. Cameron Toshack shared that his father's condition varies, with short-term memory loss being a significant challenge. However, he added that John Toshack's long-term memory remains sharp, particularly when recalling his football career. For instance, he can vividly recall details about specific matches and tactical decisions from his time at Real Madrid. Toshack's legacy in football extends beyond his playing and managerial career. As Wales manager during his second tenure from 2004 to 2010, he gave debuts to future stars like Aaron Ramsey and Gareth Bale, who played crucial roles in Wales' success, including their semi-final appearance in Euro 2016.

According to a report by IQAir, a Swiss air quality monitoring firm, Pakistan was the world's smoggiest country in 2025 with concentrations of hazardous fine particles known as PM2.5 up to 13 times higher than the World Health Organization's (WHO's) recommended level.The report, which sourced data from 9,446 cities in 143 countries, regions and territories, found that only 13 countries and territories managed to keep their average fine particulate levels below the WHO guideline, an increase from seven in 2024.Pakistan's PM2.5 level was 67.3 microgrammes per cubic metre, significantly exceeding the WHO standard of 5 microgrammes per cubic metre. In comparison, Pakistan's average PM2.5 concentration in 2024 was 73.7 microgrammes.Prolonged exposure to PM2.5 has been linked to higher likelihoods of neurodegenerative conditions, including dementia, Parkinson's disease and Alzheimer's disease.Bangladesh and Tajikistan ranked second and third on IQAir's list of the most polluted countries while Chad, statistically the smoggiest country in 2024, was in fourth place in 2025.The report also noted that Loni, a city in northern India, was identified as the world's most polluted city in 2025 with average PM2.5 levels of 112.5 microgrammes per cubic metre.Globally, only 14 percent of cities met the WHO air quality standard in 2025, down from 17 percent a year earlier. The report highlighted that wildfires, driven by climate change, were a key factor behind worsening global air quality in 2025 as record levels of biomass burning in Europe and Canada released about 1,380 megatonnes of carbon.

CrossSense, an innovative AI software, has been awarded a £1m prize for its groundbreaking technology designed to assist individuals with dementia. This cutting-edge system is integrated into smart glasses and features a user-friendly assistant named Wispy. The smart glasses, equipped with a camera, microphone, and speakers, provide wearers with real-time guidance and support through everyday tasks.Wispy offers verbal cues and text prompts that float in front of the wearer's eyes, enhancing their ability to navigate daily life. The AI assistant can also engage in light conversation, ask questions, and aid reminiscences, significantly improving the wearer's independence and quality of life.The Longitude Prize on Dementia, funded by Alzheimer's Society and Innovate UK, aims to encourage the development of technology that helps people with dementia stay independent for longer. About 150 million people are expected to be living with dementia by 2050, making such innovations crucial.The CrossSense technology is expected to cost around £50 a month per subscription, with the smart glasses potentially costing up to £1,000. However, the developers plan to make the technology more affordable over time. The team behind CrossSense plans to conduct a pilot study with smart glasses in people's homes later this year.Prof Julia Simner, who led the study, noted that participants with dementia could correctly identify 46% of household items without the glasses, increasing to 82% with the glasses. An hour after removing the glasses, the identification rate remained high at 78%.While experts praise the innovation, they also highlight the need for larger, more controlled studies to test the device's effectiveness and address ethical considerations regarding data collection and user consent.